0000000000385281

AUTHOR

Hildrun Sundseth

showing 2 related works from this author

Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults

2020

Abstract Background In 2016, an expert working group was convened under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and formulated consensus recommendations for the conduct of clinical trials for drugs to prevent or treat sarcopenia. Aims The objective of the current paper is to provide a 2020 update of the previous recommendations in accordance with the evidence that has become available since our original recommendations. Methods This paper is based on literature reviews performed by members of the ESCEO working group and followed up with face to face meetings organized for the whole group to make amendments and discuss…

AgingSarcopeniaGeriatrics & GerontologyStandardizationDiseaseReviewRecommendationsFace-to-face0302 clinical medicineQUALITY-OF-LIFEGAIT SPEEDClinical trial; Drug registration; Guidelines; Recommendations; Sarcopenia; Treatment; Aged; Humans; Muscle Strength; Osteoarthritis; Osteoporosis; Pharmaceutical Preparations; Sarcopenia030212 general & internal medicineMUSCLE MASSDIETARY-PROTEINClinical trialPhysical limitationsPharmaceutical Preparations/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingPatient-reported outcomeGRIP STRENGTHLife Sciences & Biomedicinemedicine.medical_specialtyNUTRITIONAL-STATUSBODY-COMPOSITION030209 endocrinology & metabolismGuidelines03 medical and health sciencesClinical trial · Sarcopenia · Guidelines · Recommendations · Drug registration · TreatmentSDG 3 - Good Health and Well-beingOsteoarthritismedicineHumansMuscle StrengthDrug registrationAgedScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseComorbidityClinical trialTreatmentSarcopeniaPATIENT-REPORTED OUTCOMESPhysical therapyOsteoporosisGeriatrics and GerontologyPHYSICAL PERFORMANCEbusinessAging Clinical and Experimental Research
researchProduct

Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCO…

2022

BACKGROUND Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0-14 years) and adults (aged 15-99 years) diagnosed with a haematological malignancy during 2000-14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0-24 years). METHODS We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0-14 years), adolescents (15-19 years), and young adults (20-24 years). We categorised leukaemia subtypes a…

AdolescentAustralia610 Medicine & healthlymphomaSettore MED/42 - Igiene Generale E ApplicatasurvivalUnited StatesEuropeLeukemia Myeloid AcuteYoung Adultchildrenpopulation-based/cancer registry360 Social problems & social servicessurvival leukemia cancer registryHematologic NeoplasmsleukaemiaPediatrics Perinatology and Child HealthDevelopmental and Educational PsychologycancerHumansRegistrieshaematological malignancy610 Medicine & healthChild360 Social problems & social services
researchProduct